Testing firm 23andMe has been fined more than £2m for failing to protect the sensitive personal and genetic data of more than ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

California says the sale of 23andMe to a nonprofit formed by the company's former CEO would skirt a state law specifically ...

The FTSE 100 faces a stern test of its new high levels this week, with Israel-Iran tensions still running high and Tehran ...

Anne Wojcicki’s winning bid to reclaim control of 23andMe doesn’t necessarily end the fight over what happens to the DNA of ...

To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Anne Wojcicki, co-founder and former CEO of 23andMe, will buy back “substantially all” of the genetic testing ...

Former 23andMe CEO Anne Wojcicki outbids Regeneron with a $305 million offer through her nonprofit TTAM to regain control of the DNA-testing company she co-founded.

CEO Anne Wojcicki resigned on Sunday, though she says she'll independently bid for ownership of the company she co-founded. We are a proud American independent media company that has never taken a ...

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy ...

A nonprofit run by Anne Wojcicki, the cofounder and former CEO of 23andme, has agreed to buy the genetic testing company for ...

Former CEO Anne Wojcicki has prevailed in the bankruptcy auction of 23andMe, its consumer and biopharma research businesses, ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...